Lancashire (LRE) Competitors

Lancashire (LON:LRE) and Mediclinic International (LON:MDC) are both construction companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Do analysts recommend LRE or MDC?

Lancashire currently has a consensus price target of GBX 690.25, suggesting a potential upside of 11.69%. Given Lancashire's stronger consensus rating and higher possible upside, equities analysts clearly believe Lancashire is more favorable than Mediclinic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lancashire	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Mediclinic International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, LRE or MDC?

Lancashire has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Mediclinic International has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in LRE or MDC?

60.5% of Lancashire shares are held by institutional investors. Comparatively, 39.2% of Mediclinic International shares are held by institutional investors. 0.6% of Lancashire shares are held by insiders. Comparatively, 48.9% of Mediclinic International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media prefer LRE or MDC?

In the previous week, Lancashire had 4 more articles in the media than Mediclinic International. MarketBeat recorded 4 mentions for Lancashire and 0 mentions for Mediclinic International. Lancashire's average media sentiment score of 0.77 beat Mediclinic International's score of 0.00 indicating that Lancashire is being referred to more favorably in the media.

Company	Overall Sentiment
Lancashire	Positive
Mediclinic International	Neutral

Which has preferable valuation & earnings, LRE or MDC?

Lancashire has higher earnings, but lower revenue than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lancashire	£536.12M	3.48	£199.02M	£52.49	11.77
Mediclinic International	£3.38B	0.00	£169M	£0.23	N/A

Is LRE or MDC more profitable?

Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lancashire	37.12%	10.76%	6.75%
Mediclinic International	4.99%	5.50%	2.30%

Is LRE or MDC a better dividend stock?

Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 2.9%. Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays out 34.3% of its earnings in the form of a dividend. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Lancashire beats Mediclinic International on 14 of the 17 factors compared between the two stocks.